A Phase 1b Trial of CB-839 in Combination with Radiation Therapy and Temozolomide in Patients with IDH-mutated Diffuse Astrocytoma and Anaplastic Astrocytoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Patients must have histopathologic or molecular confirmation of either IDH-mutant DA or IDH-mutant AA. 2) Patient must be at least 7 days beyond stereotactic biopsy and/or at least 14 days beyond open craniotomy at the time of registration.

You may not be eligible for this study if the following are true:

  • 1) Patients must not have received prior chemotherapy to treat the glioma. 2) Patients who are receiving any other investigational agents.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.